NCT07466602

cfDNA Methylation for Liver Cancer Recurrence Detection

Clinical Study on the Combined Detection of Plasma GNB4 and Riplet Gene Methylation for Monitoring Primary Liver Cancer Recurrence

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: Wuhan Ammunition Life-tech Co., Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Through follow-up testing of patients with primary liver cancer who underwent hepatectomy, liver transplantation, ablation therapy, or transarterial chemoembolization (TACE), a blinded comparative trial was conducted at each monitoring site. This trial evaluated the combined methylation detection kit for GNB4 and Riplet genes (fluorescent PCR method) against the clinical reference standard (defined as the physician's comprehensive diagnosis based on clinical guidelines and other criteria). The study evaluated the clinical performance of the assay in diagnosing primary liver cancer recurrence and validated the clinical efficacy of methylation detection kits for monitoring recurrence after primary liver cancer treatment.

Conditions

• Primary Liver Cancer

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	plasma GNB4 and Riplet genes methylation detection	Liver cancer patients undergo methylation testing at different follow-up time points after treatment

Timeline

• Start date: 2025-09-02
• Primary completion: 2027-06-30
• Completion: 2027-12-31
• First posted: 2026-03-12
• Last updated: 2026-03-23

Locations

1 site across 1 country: China